Search
Buchang Pharmaceutical Announces Drug Registration Approval for Quadrivalent Influenza Vaccine by Subsidiary Zhejiang Tianyuan Biopharmaceutical
2 week ago /
Read about 0 minute
Author：小编
Buchang Pharmaceutical's subsidiary, Zhejiang Tianyuan Biopharmaceutical Co., Ltd., has secured the Drug Registration Certificate for its Quadrivalent Influenza Virus Split Vaccine, which has been approved and issued by the National Medical Products Administration. This vaccine is designed to prevent influenza, and by June 30, 2025, the company had invested a substantial amount of approximately RMB 126 million in research and development costs for this project.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
